In this article, we make the case for a better common understanding among payers, companies and regulators of medicine pricing to avoid future conflicts or standstill in price negotiations.
The case for a better mutual understanding is a strong one as the price that a company can expect to charge for a medicinal product acts as a crucial investment incentive. In times of a growing global gap about pricing of medicines, understanding the investor perspective of what constitutes a fair bet becomes increasingly important.
For further information, please contact Managing Economist Julia Sabine Wahl